HighVista Strategies’s Cymabay Therapeutics CBAY Stock Holding History

HighVista Strategies’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-160,334	Closed	-$3.79M	–	162
2023 Q4	$3.79M	Sell	160,334 -19,971	-11%	-$356K	1.37%	20
2023 Q3	$2.69M	Sell	180,305 -158,537	-47%	-$2.1M	1.24%	22
2023 Q2	$3.71M	Sell	338,842 -8,944	-3%	-$83.3K	1.7%	8
2023 Q1	$3.03M	Sell	347,786 -47,546	-12%	-$381K	2.47%	9
2022 Q4	$2.48M	Hold	395,332	–	–	1.47%	21
2022 Q3	$1.38M	Hold	395,332	–	–	0.79%	35
2022 Q2	$1.17M	Buy	395,332 +188,025	+91%	+$449K	0.7%	34
2022 Q1	$645K	Buy	+207,307	New	+$653K	0.41%	63
2021 Q1	–	Sell	-116,519	Closed	-$669K	–	147
2020 Q4	$669K	Buy	+116,519	New	+$882K	0.43%	57

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HighVista Strategies's CBAY Position: Q1 2024 in Review

HighVista Strategies sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 160,334 shares — an estimated $3.79M sold.

HighVista Strategies first reported a position in CBAY in Q4 2020 and held it in 9 quarters. The position peaked at $3.79M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

HighVista Strategies reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
HighVista Strategies sold 160,334 Cymabay Therapeutics shares in Q1 2024, an estimated $3.79M.
HighVista Strategies first reported a position in Cymabay Therapeutics in Q4 2020 and held it in 9 quarters.
HighVista Strategies's Cymabay Therapeutics position peaked at $3.79M in Q4 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on HighVista Strategies's 13F filing for Q1 2024, filed 15 May 2024.